MYR Exit

MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

Press releases

10. December 2020

Most Successful Exit in the History of High-Tech Gründerfonds – Gilead Sciences to Acquire MYR GmbH

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 yearsMYR developed HepcludexTM (Bulevirtide), a first-in-class entry inhibitor for the treatment of chronic hepatitis delta virus (HDV). Hepcludex was conditionally approved in Europe by the EMA in July 2020 and submission for accelerated approval in the United States is anticipated by second half of 2021The acquisition builds on Gilead’s strength as a global leader in virology and liver diseases with ad
31. October 2014
MYR GmbH Announces 10 million $ Financing Round After Successful Clinical Phase 2a
Further product development to combat hepatitis delta virus infection received a boost today thanks to commitments from MYR GmbH investors Maxwell Biotech Venture Fund and High-Tech Gruenderfonds. The combined investment of 7.9 million Euro (approximately $10 million) will be used by MYR for further development of Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and D (HDV) virus infections. Dmitri Popov, Managing Partner of Maxwell Biotech Fund said: “W
21. March 2012
Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program
Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds Maxwell Biotech Venture Fund (MBVF), founded with the participation of the Russian Government’s Russian Venture Company, announced today its first investment involving the High-Tech Gründerfonds (HTGF), one of Europe’s largest venture funds. MBVF’s investment committee approved the terms and the amount of an investment in a newly formed Russian biotech company, Hepatera, and a concurr
12. May 2011
High-Tech Gründerfonds invests in a novel Hepatits B compound
German Biotech MYR GmbH develops the viral entry inhibitor Myrcludex, a so-called „first-in-class“ drug for the treatment of chronic hepatitis B and D infections. The HTGF investment of 500,000 € enables the start of Phase 1 of clinical development already in summer 2011. MYR develops its lead compound in close collaboration with the University Clinic Heidelberg, one of the world-leading centers for biomedical research. The pre-clinical studies have been successfully completed. Myrclude

Info & Contact

Dimitry Popov


Eiermarkt 3c
30938 Burgwedel

In portfolio

21. Jan 2011 – 09. Dec 2020

HTGF Manager

Dr. Bernd Goergen, Partner